Stockscreener 앱 받기
44.32
4.30%
-1.99
시장 영업 전:
45.24
0.92
+2.08%
전일 마감가:
$46.31
열려 있는:
$46.27
하루 거래량:
2.71M
Relative Volume:
1.13
시가총액:
$36.88B
수익:
$27.43B
순이익/손실:
$1.27B
주가수익비율:
28.00
EPS:
1.5829
순현금흐름:
$1.01B
1주 성능:
+2.36%
1개월 성능:
+0.43%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$44.00
$46.90
1주일 범위
$43.41
$46.90
52주 변동 폭
$38.50
$46.90
Medline Inc Stock (MDLN) Company Profile
MDLN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MDLN
Medline Inc
|
44.32 | 38.54B | 27.43B | 1.27B | 1.01B | 1.5829 |
|
ISRG
Intuitive Surgical Inc
|
522.04 | 186.12B | 10.06B | 2.88B | 2.27B | 7.8807 |
|
BDX
Becton Dickinson Co
|
201.92 | 57.95B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
80.42 | 39.72B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
257.72 | 37.29B | 5.26B | 1.44B | 1.76B | 9.7713 |
Medline Inc Stock (MDLN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-21 | 재확인 | BTIG Research | Buy |
| 2026-01-12 | 개시 | Citigroup | Buy |
| 2026-01-12 | 개시 | Deutsche Bank | Hold |
| 2026-01-12 | 개시 | Evercore ISI | Outperform |
| 2026-01-12 | 개시 | Goldman | Buy |
| 2026-01-12 | 개시 | JP Morgan | Overweight |
| 2026-01-12 | 개시 | Jefferies | Buy |
| 2026-01-12 | 개시 | Leerink Partners | Outperform |
| 2026-01-12 | 개시 | Mizuho | Outperform |
| 2026-01-12 | 개시 | Morgan Stanley | Overweight |
| 2026-01-12 | 개시 | Piper Sandler | Overweight |
| 2026-01-12 | 개시 | RBC Capital Mkts | Outperform |
| 2026-01-12 | 개시 | Robert W. Baird | Outperform |
| 2026-01-12 | 개시 | Rothschild & Co Redburn | Neutral |
| 2026-01-12 | 개시 | Stifel | Buy |
| 2026-01-12 | 개시 | TD Cowen | Buy |
| 2026-01-12 | 개시 | Truist | Buy |
| 2026-01-12 | 개시 | UBS | Buy |
| 2026-01-12 | 개시 | Wells Fargo | Equal Weight |
| 2026-01-12 | 개시 | William Blair | Outperform |
| 2026-01-12 | 개시 | Wolfe Research | Outperform |
모두보기
Medline Inc 주식(MDLN)의 최신 뉴스
Medline to report fourth quarter and full year 2025 results on February 25, 2026 - GlobeNewswire
Is It Time To Reassess Medline (MDLN) After Its Recent Share Price Climb - Yahoo Finance
Medline Inc (MDLN) Shares Up 3.65% on Jan 22 - GuruFocus
Jim Cramer Says Medline "Stock Is Unbelievable" And Recommends Buying It - Finviz
Jim Cramer Says Medline “Stock Is Unbelievable” And Recommends Buying It - Yahoo Finance
Medline Industries: Solid Physical Moat With Visible Earnings Growth Runway (NASDAQ:MDLN) - Seeking Alpha
Jim Cramer Recently Looked at These 25 Stocks - Insider Monkey
Is There An Opportunity In Medline (MDLN) After Recent DCF Valuation Results - Sahm
Pointcore Supply Chain Services members select Medline as distributor - Medline Newsroom
Ranpak expands packaging automation partnership with Medline - Packaging Insights
In face of uncertainty and tariffs, newly public Medline sticks to the old formula - chicagobusiness.com
Ranpak in Collaboration with Medline - Medical Device and Diagnostic industry
Medline Shares Climb as Analysts Launch Coverage After $7.2 Bill - GuruFocus
Medline Shares Climb as Analysts Launch Coverage After $7.2 Billion IPO - Yahoo Finance
Ranpak and Medline Partner to for High-Volume Distribution Operations From: Ranpak Corporation - Healthcare Packaging
Ranpak Holdings Corp. and Medline Partner to Advance Automation and Sustainable Packaging Across High-Volume Distribution Operations - marketscreener.com
Ranpak and Medline Partner to Advance Automation and Sustainable Packaging Across High-Volume Distribution Operations - Business Wire
Analysts Are Bullish on These Healthcare Stocks: Exagen (XGN), Medline, Inc. Class A (MDLN) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Medline, Inc. Class A (MDLN) and IDEAYA Biosciences (IDYA) - The Globe and Mail
Medline jumps as analysts bullish after 2025’s top IPO - The Daily Gazette
Medline Jumps as Analysts Bullish After 2025’s Top IPO - Bloomberg
Analysts initiate coverage on Medline after IPO, flag growth visibility and margin - Investing.com
Why Is Medline Stock Gaining Monday?Medline (NASDAQ:MDLN) - Benzinga
Analysts Say Medline Has The Secret Sauce For Sustained Growth - Sahm
Is Medline (MDLN) Fairly Priced After Recent Share Price Stability? - Yahoo Finance
Analysts initiate Medline with bullish ratings after blockbuster IPO - Reuters
TD Cowen initiates Medline stock with Buy rating on market share growth - Investing.com Nigeria
BTIG initiates coverage on Medline stock with Buy rating, $50 target By Investing.com - Investing.com South Africa
Wells Fargo & Company Begins Coverage on Medline (NASDAQ:MDLN) - MarketBeat
This Netflix Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Medline initiated with a Buy at BTIG - TipRanks
Goldman Sachs Initiates Coverage on Medline With Buy Rating, $49 Price Target - marketscreener.com
BMO Capital Initiates Coverage on Medline With Outperform Rating, $45 Price Target - marketscreener.com
JPMorgan Initiates Coverage on Medline With Overweight Rating, $50 Price Target - marketscreener.com
William Blair initiates Medline stock with Outperform rating By Investing.com - Investing.com South Africa
BTIG initiates coverage on Medline stock with Buy rating, $50 target - Investing.com Nigeria
Wells Fargo initiates coverage on Medline stock with Equal Weight rating - Investing.com Nigeria
BofA Securities initiates Medline stock with Buy rating, $50 price target - Investing.com Nigeria
Analysts initiate Medline with bullish ratings after blockbuster IPO By Reuters - Investing.com
Medline initiated with an Outperform at Mizuho - TipRanks
RBC Initiates Medline at Outperform With $47 Price Target - marketscreener.com
Medline (MDLN) Valuation Check As Shares Trade Near DCF Fair Value And Sector P/E Discount - Sahm
William Blair initiates Medline stock with Outperform rating - Investing.com
Medline: Vertically Integrated Growth Leader With Prime Vendor Advantage Supporting Buy-Rated Risk/Reward - TipRanks
Medline, Inc. Class A: Prime Vendor Wins, Branded Mix Shift, and Margin Expansion Support Buy Rating and Premium Valuation - TipRanks
Medline: Prime Vendor Flywheel, Durable Growth, and Supportive Valuation Underscore Overweight/Buy Rating - TipRanks
Mizuho initiates Medline stock with Outperform rating, $48 price target By Investing.com - Investing.com India
Mizuho initiates Medline stock with Outperform rating, $48 price target - Investing.com
Analysts start coverage on Medline with bullish ratings - TradingView — Track All Markets
BMO Capital initiates Medline stock with Outperform rating, $45 target By Investing.com - Investing.com Nigeria
JPMorgan initiates Medline stock with Overweight rating, $50 price target By Investing.com - Investing.com Nigeria
Medline Inc (MDLN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.56%
자본화:
|
볼륨(24시간):